A Study on the Korean Translation of the Character ‘爲’ in the Mencius
The Society for Chinese Humanities in Korea · 30.04.2026 · 92 · 39-60
DOI: 10.35955/jch.2026.04.92.39 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Society for Chinese Humanities in Korea, online erschienen am 30.04.2026. Verfasst von Nak-shin Jung.
Abstract (Originalsprache)
This study aims to help beginning learners understand the Korean translations of the character ‘爲’ in the Mencius, thereby enhancing the ease of reading the text and, on this basis, improving literacy in other classical Chinese works. The character ‘爲’ is defined in the Shuowen Jiezi(說文解字) as “作也” (“to act”), and is generally translated as “to do,” “for the sake of,” or “to become.” However, in actual classical Chinese translation, the interpretation of ‘爲’ varies depending on its combination with surrounding characters and the broader context. Some dictionaries list 45 glosses beginning with “to do, to handle,” and provide 111 specific lexical items. In addition, there exists a substantial body of prior research related to grammar. This study was undertaken with the question of how such reference works and prior scholarship can assist beginners in reading classical Chinese texts. Through an analysis of the Korean translations of ‘爲’ in Mencius, the study demonstrates that comprehension of the text is possible with only seven to eight basic glosses.
Zitieren
APA
Jung, N. (2026). A Study on the Korean Translation of the Character ‘爲’ in the Mencius. The Society for Chinese Humanities in Korea, 92, 39-60. https://doi.org/10.35955/jch.2026.04.92.39
Vancouver
Jung N. A Study on the Korean Translation of the Character ‘爲’ in the Mencius. The Society for Chinese Humanities in Korea. 2026;92:39-60. doi:10.35955/jch.2026.04.92.39
BibTeX
@article{Jung2026,
author = {Jung, Nak-shin},
title = {A Study on the Korean Translation of the Character ‘爲’ in the Mencius},
journal = {The Society for Chinese Humanities in Korea},
year = {2026},
volume = {92},
pages = {39--60},
doi = {10.35955/jch.2026.04.92.39}
}
EUVIMED